Navidea Biopharmaceuticals Inc (NAVB):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Navidea Biopharmaceuticals Inc (NAVB) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7224
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Navidea Biopharmaceuticals Inc (Navidea) is a biopharmaceutical company that develops precision immunodiagnostic agents and immunotherapeutics.. The company is focused on developing multiple precision-targeted products based on its Manocept platform to improve patient care. Its pipeline products include MT-1002; MT-2002; Tc99m tilmanocept for Kaposi’s, NAS, Cardiovascular diseases, Sentinal Node Biopsy, and Solid tumors lymphatic mapping and NAV4694 for Alzhemier’s Disease. Navidea by utilizing its Manocept platform develops multiple precision-targeted products to identify pathways of undetected disease and provide better diagnostic accuracy, clinical decision-making and effective treatment. The company has presence in the US, and the UK. Navidea is headquartered in Dublin, Ohio, the US.

Navidea Biopharmaceuticals Inc (NAVB) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Navidea Biopharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Navidea Biopharmaceuticals Inc, Medical Equipment, Deal Details 10
Partnerships 10
Sayre Therapeutics Enters into Licensing Agreement with Navidea Biopharma 10
Cerveau to Enter into Licensing Agreement with Navidea Biopharma 11
Equity Offering 12
Navidea Biopharma Raises USD3 Million in Private Placement of Shares 12
Navidea Biopharma Plans to Raise up to USD100 in Public Offering of Shares 13
Navidea Biopharma Completes Private Placement Of Units For US$30 Million 14
Navidea Biopharma Completes Public Offering Of Common Stock For US$5 Million 16
Navidea Biopharma Completes Private Placement Of Shares For US$5 Million 17
Navidea Biopharma Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 19
Navidea Biopharmaceuticals Inc – Key Competitors 20
Navidea Biopharmaceuticals Inc – Key Employees 21
Navidea Biopharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Aug 08, 2018: Navidea Biopharmaceuticals reports second quarter 2018 financial results 23
May 08, 2018: Navidea Biopharmaceuticals Announces First Quarter 2018 Financial Results 24
Mar 08, 2018: Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 25
Nov 08, 2017: Navidea Biopharmaceuticals Reports Third Quarter 2017 Financial Results 27
May 09, 2017: Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results 29
Mar 29, 2017: Navidea Provides Corporate Update and Reports Full Year 2016 Results 31
Corporate Communications 34
Aug 17, 2018: Navidea Biopharmaceuticals announces results of the Annual Shareholder Meeting 34
Legal and Regulatory 35
Aug 15, 2018: Navidea Biopharmaceuticals receives noncompliance notice from NYSE American 35
Product News 36
Nov 01, 2017: Navidea to Present Late-Breaking Abstract at American College of Rheumatology Annual Meeting 36
Apr 25, 2017: Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Navidea Biopharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Navidea Biopharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Navidea Biopharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 8
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Sayre Therapeutics Enters into Licensing Agreement with Navidea Biopharma 10
Cerveau to Enter into Licensing Agreement with Navidea Biopharma 11
Navidea Biopharma Raises USD3 Million in Private Placement of Shares 12
Navidea Biopharma Plans to Raise up to USD100 in Public Offering of Shares 13
Navidea Biopharma Completes Private Placement Of Units For US$30 Million 14
Navidea Biopharma Completes Public Offering Of Common Stock For US$5 Million 16
Navidea Biopharma Completes Private Placement Of Shares For US$5 Million 17
Navidea Biopharma Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 19
Navidea Biopharmaceuticals Inc, Key Competitors 20
Navidea Biopharmaceuticals Inc, Key Employees 21
Navidea Biopharmaceuticals Inc, Subsidiaries 22

List of Figures
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Navidea Biopharmaceuticals Inc (NAVB):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Jacobs Engineering Group Inc (JEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Jacobs Engineering Group Inc (Jacobs) is a professional services company. It offers a diverse range of technical, professional, and construction services. The company's service portfolio includes project; process, scientific and specialty consulting; engineering and construction; and operati …
  • Yaskawa Electric Corp:企業の戦略・SWOT・財務分析
    Yaskawa Electric Corp - Strategy, SWOT and Corporate Finance Report Summary Yaskawa Electric Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • University of Wisconsin Madison-製薬・医療分野:企業M&A・提携分析
    Summary University of Wisconsin Madison (UW-Madison), a subsidiary of University of Wisconsin System is an educational and research institution that provides undergraduate and postgraduate courses. The institution offers courses in various fields such as agricultural and life sciences, arts, busines …
  • Celanese Corp (CE):企業の財務・戦略的SWOT分析
    Celanese Corp (CE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Summit Therapeutics Plc (SUMM):企業の財務・戦略的SWOT分析
    Summary Summit Therapeutics Plc (Summit), formerly Summit Corp Plc is a clinical-stage drug discovery and development company that offer therapies. The company conducts research and development on the treatment of rare diseases and infectious diseases including duchenne muscular dystrophy and the in …
  • OncoTartis Inc-製薬・医療分野:企業M&A・提携分析
    Summary OncoTartis Inc (OncoTartis) is a biotechnology company with a focus on development of various treatments for various types of cancers. Its lead candidate OT-82, an orally available NicotinAMide Phosphoribosyl Transferase inhibitor, is being developed for treating broad range of leukemias and …
  • The Centre of Excellence for Prevention of Organ Failure:医療機器:M&Aディール及び事業提携情報
    Summary The Centre of Excellence for Prevention of Organ Failure (PROOF Centre) is a healthcare center that provides blood-based biomarker tests. The center conducts biomarker programs to develop simple blood tests for transplant patients and patients with chronic organ disease and biomarkers in tra …
  • Deutsche Telekom AG (DTE):企業の財務・戦略的SWOT分析
    Deutsche Telekom AG (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Empresas Copec S.A.:企業の戦略・SWOT・財務分析
    Empresas Copec S.A. - Strategy, SWOT and Corporate Finance Report Summary Empresas Copec S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • BORSIG ZM Compression GmbH:企業の戦略的SWOT分析
    BORSIG ZM Compression GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Societe Generale Private Banking:企業の戦略・SWOT・財務分析
    Societe Generale Private Banking - Strategy, SWOT and Corporate Finance Report Summary Societe Generale Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Twist Bioscience Corp (TWST):医療機器:M&Aディール及び事業提携情報
    Summary Twist Bioscience Corp (Twist Bioscience) is a provider of synthetic DNA Tools. Its silicon-based DNA synthesis platform enables precise synthesis and sequencing process and production of synthetic DNA tools. The company offers its products which include DNA tools for gRNA cloning such as una …
  • Acer Therapeutics Inc (ACER):医療機器:M&Aディール及び事業提携情報
    Summary Acer Therapeutics Inc (Acer), formerly Opexa Therapeutics Inc is a pharmaceutical company that offers acquisition, development and commercialization of therapies for patients with serious rare diseases. The company offers treatment of autoimmune disorders, rheumatoid arthritis, diabetes and …
  • Elecnor SA (ENO):電力:M&Aディール及び事業提携情報
    Summary Elecnor SA (Elecnor) is an engineering and construction company. It specializes in engineering, development and construction of projects relating to infrastructure, renewable energies and new technologies. The company focuses on end-to-end management of electricity, power generation, telecom …
  • B. Braun Melsungen AG:戦略・SWOT・企業財務分析
    B. Braun Melsungen AG - Strategy, SWOT and Corporate Finance Report Summary B. Braun Melsungen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Salvatore Ferragamo SpA (SFER):企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Telecom Argentina S.A.:企業の戦略・SWOT・財務分析
    Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report Summary Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Klox Technologies Inc-製薬・医療分野:企業M&A・提携分析
    Summary Klox Technologies Inc (Klox Technologies) is a specialty pharmaceutical company, which focuses on the development and commercialization of a proprietary BioPhotonic technology platform. Its pipeline portfolio includes non-invasive wound care treatment solutions, dermatological treatment solu …
  • Mechel:企業の戦略・SWOT・財務情報
    Mechel - Strategy, SWOT and Corporate Finance Report Summary Mechel - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Latvenergo AS:企業の戦略的SWOT分析
    Latvenergo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆